Merck and Moderna announced on August 19 that their experimental personalized mRNA cancer vaccine met its primary endpoint in a late-stage clinical trial for patients with high-risk melanoma, according to STAT News. The Phase 3 study tested the vaccine, known as mRNA-4157 or V940, in combination with Merck’s blockbuster immunotherapy drug Keytruda in patients who had surgically removed melanoma tumors but faced a high risk of recurrence.
The companies said the combination significantly reduced the risk of cancer recurrence or death compared with Keytruda alone, clearing the bar regulators typically require before considering approval. Detailed data have not yet been published in a peer-reviewed journal, but Merck and Moderna indicated they intend to present full results at an upcoming medical conference and pursue regulatory filings with the U.S. Food and Drug Administration.
How the Vaccine Works
Unlike traditional vaccines designed to prevent infection, mRNA-4157 is a therapeutic, individualized treatment built for each patient. After a tumor is surgically removed, researchers sequence its genetic mutations to identify neoantigens — proteins unique to that patient’s cancer cells. Moderna’s mRNA platform, the same technology behind its COVID-19 vaccine, then encodes instructions for up to 34 of those neoantigens into a single shot.
Once injected, the mRNA prompts the patient’s own cells to produce these tumor-specific proteins, training the immune system to recognize and attack any remaining cancer cells that could cause a relapse. Because each vaccine is manufactured from an individual patient’s tumor biopsy, the approach represents a shift from one-size-fits-all cancer drugs toward precision medicine tailored at the molecular level.
Building on Earlier Results
The Phase 3 trial follows a smaller Phase 2b study, known as KEYNOTE-942, which first suggested the vaccine-Keytruda combination could meaningfully lower recurrence rates in melanoma patients. That earlier trial reported a substantial reduction in the risk of cancer recurrence or death, along with a notable drop in the risk of distant metastasis, when the vaccine was added to Keytruda following surgery. Those results, first disclosed in 2023, prompted the FDA to grant the combination breakthrough therapy designation, fast-tracking its development.
The newly completed larger trial, which enrolled patients across multiple countries, was designed to confirm those earlier findings in a more rigorous, statistically powered setting — a standard requirement before a therapy can move toward broad approval.
“This is a landmark moment for the field of cancer immunotherapy,” the companies said in a joint statement, noting that the approach could eventually extend beyond melanoma to other solid tumors currently in earlier stages of testing, including lung and kidney cancers.
What Comes Next
Melanoma is among the most aggressive forms of skin cancer, and while early-stage cases are often curable with surgery alone, patients with high-risk disease face a substantial chance of recurrence even after tumors are removed. Keytruda, a checkpoint inhibitor that helps the immune system detect cancer cells, is already a standard treatment for these patients, but doctors have long sought ways to further reduce relapse risk.
If regulators approve the vaccine-Keytruda combination, it would become the first mRNA-based cancer treatment to reach the market, a milestone that oncologists have anticipated since the technology’s rapid development during the COVID-19 pandemic demonstrated how quickly mRNA platforms could be adapted for new targets. Manufacturing remains a key hurdle: each dose must be custom-built from a patient’s own tumor tissue, a process that takes weeks and requires specialized production capacity that Moderna has been scaling up at facilities in Massachusetts and abroad.
Cost and access will also shape how quickly the therapy reaches patients. Personalized cancer treatments have historically carried steep price tags, and insurers, hospital systems, and national health services will need to determine how to cover a therapy manufactured individually for each patient rather than produced at scale like a conventional drug.
Broader Implications for Cancer Research
Beyond melanoma, Merck and Moderna are already testing the same mRNA platform in trials for non-small cell lung cancer and other solid tumors, betting that the neoantigen approach could generalize across cancer types with high mutation burdens. Success in the melanoma trial gives that broader research program a significant boost, potentially accelerating investment and enrollment in follow-on studies.
The announcement also lands amid renewed public attention on mRNA technology, which became a household term during the pandemic but has faced scrutiny and political controversy in some quarters since. Researchers say cancer applications represent a distinct use case from infectious disease vaccines, since the goal is to train the immune system against a patient’s own mutated cells rather than an external pathogen.
Merck and Moderna have not provided a specific timeline for an FDA submission, but analysts following the companies expect a filing within the next year if the full trial data, once published, hold up to regulatory scrutiny. For now, the companies say they are working to make the full results available to the scientific community as quickly as possible.
